SRR6013579
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ADIPOGENESIS+0.320
- FATTY_ACID_METABOLISM+0.320
- NOTCH_SIGNALING+0.320
- ANDROGEN_RESPONSE+0.270
- HEME_METABOLISM+0.260
- PROTEIN_SECRETION+0.240
- UV_RESPONSE_DN+0.220
- CHOLESTEROL_HOMEOSTASIS+0.200
- OXIDATIVE_PHOSPHORYLATION+0.190
- PEROXISOME+0.160
Top 10 suppressed
- G2M_CHECKPOINT-0.480
- E2F_TARGETS-0.470
- ALLOGRAFT_REJECTION-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- APICAL_SURFACE-0.330
- IL6_JAK_STAT3_SIGNALING-0.320
- PANCREAS_BETA_CELLS-0.310
- SPERMATOGENESIS-0.290
- INFLAMMATORY_RESPONSE-0.280
- MYC_TARGETS_V2-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-8281-01A-11R-2287-07 | — | cohortA2 | 0.850 |
| 2 | SRR6013601 | — | cohortA1 | 0.844 |
| 3 | SRR6013557 | — | cohortA1 | 0.834 |
| 4 | TCGA-50-5932-01A-11R-1755-07 | — | cohortA2 | 0.834 |
| 5 | TCGA-44-6146-01A-11R-A278-07 | — | cohortA1 | 0.829 |
| 6 | BS_17WYVEEC | pilocytic astrocytoma | — | 0.795 |
| 7 | f7683b51.cca9.4079.9e34.b9a4fdd27d85 | — | cohortA1 | 0.791 |
| 8 | X2ea5b654.8b53.4e39.8f1a.129a46474ae2 | — | cohortA1 | 0.790 |
| 9 | SJEPD031750_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.784 |
| 10 | TCGA-E2-A1IU-01A-11R-A14D-07 | — | B | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |